Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington’s Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
Three poster presentations highlight the role of NMDA receptor dysfunction in Huntington’s Disease related cognitive impairment and potential for positive…